DiaMedica Therapeutics (NASDAQ:DMAC) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a research report sent to investors on Friday,Benzinga reports. The firm currently has a $7.00 price target on the stock.

Separately, Oppenheimer restated an “outperform” rating and set a $6.00 target price on shares of DiaMedica Therapeutics in a report on Friday, August 16th.

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC traded down $0.11 during mid-day trading on Friday, reaching $4.01. 75,701 shares of the company’s stock traded hands, compared to its average volume of 49,986. The company has a 50 day moving average price of $4.30 and a 200-day moving average price of $3.57. The firm has a market capitalization of $171.43 million, a price-to-earnings ratio of -7.16 and a beta of 1.46. DiaMedica Therapeutics has a 12-month low of $2.14 and a 12-month high of $4.95.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Blue Trust Inc. bought a new stake in DiaMedica Therapeutics in the third quarter worth $185,000. Vanguard Group Inc. lifted its stake in shares of DiaMedica Therapeutics by 26.3% in the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock worth $2,807,000 after buying an additional 211,351 shares in the last quarter. Magnolia Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics during the second quarter valued at approximately $87,000. Geode Capital Management LLC raised its holdings in DiaMedica Therapeutics by 29.6% in the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after acquiring an additional 70,070 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in DiaMedica Therapeutics in the 3rd quarter valued at approximately $40,000. Institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.